BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy. METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation. RESULTS: IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, "aberration-rich" cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer. CONCLUSIONS: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment.
BACKGROUND:IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy. METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation. RESULTS:IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, "aberration-rich" cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer. CONCLUSIONS: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancerpatients may benefit from such a treatment.
Authors: Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten Journal: Nature Date: 2014-06-25 Impact factor: 49.962
Authors: Martin Glas; Oliver Bähr; Jörg Felsberg; Katja Rasch; Dorothee Wiewrodt; Martin Schabet; Matthias Simon; Horst Urbach; Joachim P Steinbach; Johannes Rieger; Rolf Fimmers; Michael Bamberg; Thomas Nägele; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: Ann Neurol Date: 2011-06-27 Impact factor: 10.422
Authors: Mi Ran Kang; Min Sung Kim; Ji Eun Oh; Yoo Ri Kim; Sang Yong Song; Seong Il Seo; Ji Youl Lee; Nam Jin Yoo; Sug Hyung Lee Journal: Int J Cancer Date: 2009-07-15 Impact factor: 7.396
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Guido Sauter; Stefan Steurer; Till Sebastian Clauditz; Till Krech; Corinna Wittmer; Florian Lutz; Maximilian Lennartz; Tim Janssen; Nayira Hakimi; Ronald Simon; Mareike von Petersdorff-Campen; Frank Jacobsen; Katharina von Loga; Waldemar Wilczak; Sarah Minner; Maria Christina Tsourlakis; Viktoria Chirico; Alexander Haese; Hans Heinzer; Burkhard Beyer; Markus Graefen; Uwe Michl; Georg Salomon; Thomas Steuber; Lars Henrik Budäus; Elena Hekeler; Julia Malsy-Mink; Sven Kutzera; Christoph Fraune; Cosima Göbel; Hartwig Huland; Thorsten Schlomm Journal: Eur Urol Date: 2015-11-02 Impact factor: 20.096
Authors: Tom H Peeters; Krissie Lenting; Vincent Breukels; Sanne A M van Lith; Corina N A M van den Heuvel; Remco Molenaar; Arno van Rooij; Ron Wevers; Paul N Span; Arend Heerschap; William P J Leenders Journal: Cancer Metab Date: 2019-05-20
Authors: Caroline N Barquilha; Nilton J Santos; Caio C D Monção; Isabela C Barbosa; Flávio O Lima; Luis A Justulin; Nelma Pértega-Gomes; Sérgio L Felisbino Journal: Oxid Med Cell Longev Date: 2020-01-20 Impact factor: 6.543
Authors: Christoph Fraune; Eike Burandt; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Doris Höflmayer; Niclas Ch Blessin; Tim Mandelkow; Wenchao Li; Daniel Perez; Jakob R Izbicki; Waldemar Wilczak; Guido Sauter; Jörg Schrader; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Till S Clauditz; Stefan Steurer Journal: Ann Surg Oncol Date: 2020-02-27 Impact factor: 4.339